- Home
- OSRH vs BCAB Comparison
OSRH vs BCAB Comparison
Compare OSRH & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OSRH | BCAB |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | 61 |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.4M | 20.8M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | OSRH | BCAB |
|---|---|---|
| Price | $0.63 | $0.31 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | ★ 2.9M | 2.8M |
| Earning Date | 02-24-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.45 | $0.24 |
| 52 Week High | $11.84 | $1.43 |
Technical Indicators
Market Signals| Indicator | OSRH | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 46.39 | 32.72 |
| Support Level | $0.69 | $0.29 |
| Resistance Level | $0.84 | $0.39 |
| Average True Range (ATR) | 0.09 | 0.05 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 21.00 | 17.14 |
Price Performance
Historical ComparisonAbout OSRH OSR Holdings Inc.
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.